Alterity Therapeutics Limited (ATHE)
Chart Events
Performance Outlook
| Previous Close | 0.5994 |
| Open | 0.6250 |
| Bid | 0.6104 x 3100 |
| Ask | 0.6200 x 800 |
| Day's Range | 0.6000 - 0.6349 |
| 52 Week Range | 0.5600 - 1.4000 |
| Volume | |
| Avg. Volume | 76,035 |
| Market Cap | 26.627M |
| Beta (5Y Monthly) | 1.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3600 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
Is Alterity Therapeutics (ASX:ATH) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- PR Newswire
Alterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash Flow Report
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30th June 2022 (Q4 FY22).
- PR Newswire
Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first patient has been dosed in the Company's Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.
